Sygnature Discovery to co-host Predictive Toxicology in Discovery DMPK conference
Private equity-backed Sygnature Discovery, the UK’s largest independent provider of integrated drug discovery resource and expertise, is to co-host a symposium in Predictive Toxicology in Discovery DMPK at BioCity Nottingham on 22nd March 2018.
This one-day meeting will provide a forum for the exchange of ideas between members of the DMPK and toxicology research communities. Talks from thought leaders in industry and academia will provide global perspectives on how predictive toxicology platforms have evolved and became key to the drug discovery and development process. A range of ‘hot topics’ will be discussed, with a key theme being the central importance of understanding and harnessing underpinning toxicology concepts. The emphasis will be on building dialogue between participants, who will range from experienced project/laboratory leaders to early-career researchers from industry and academic institutions. The meeting will offer a variety of talks complemented by short oral presentations and poster presentations, as well as plenty of opportunities for networking throughout.
To register for this event, just click here. Registration is free for DMDG members.